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Factors predicting the outcome of intravenous 
thrombolysis in stroke patients before rt-PA 
administration 
 
Abstract 
Background: To determine whether it is possible to predict intravenous thrombolytic 
therapy (IVT) outcome after 3 months in acute ischemic stroke patients who are candidate 
to receive recombinant tissue plasminogen activator (rt-PA), before rt-PA administration 
based on their risk factors and some available laboratory results. 
Methods: We enrolled 118 ischemic stroke patients who were treated with standard dose 
of Alteplase in our hospital. Baseline characteristics, door-to-needle time (DTN), onset-to-
treatment time (OTT), the National Institute Health Stroke Scale (NIHSS), systolic and 
diastolic blood pressure on admission, history of diabetes, hypertension, dyslipidemia, 
coronary artery disease (CAD), previous ischemic stroke, atrial fibrillation (AF), 
laboratory results were retrospectively collected. The modified Rankin Scale (mRS) was 
recorded after 3 months of admission and patients were divided into good (mRS 2) and 
poor (mRS>2) outcome groups. Chi-square test and t-test were used for categorical and 
continuous variables, respectively. Predictors for outcome after 3 months were studied by 
multivariable logistic regression. 
Results: Good outcome was seen in 60 (51%) patients and poor outcome was seen in 58 
(49%) patients. Significant predictors for outcome at 3 months according to multivariable 
regression analysis were NIHSS score (odds ratio [OR], 0.61; 95% confidence interval 
[CI], 0.498-0.750; p<0.001), SBP (OR, 0.95; 95% CI, 0.925-0.991; P=0.01), AF (OR, 
0.09; 95% CI, 0.013- 0.708; P=0.02), CAD (OR, 17.08; 95% CI, 0.013-0.708; p=0.003). 
Conclusion: Higher NIHSS score, higher SBP on admission, AF and history of CAD 
could be the independent predictors of outcome after IVT in acute ischemic stroke 
patients. 
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Intravenous recombinant tissue plasminogen activator (IV rt-PA) in proper patients 
within 4.5 hours of symptom onset, is the main treatment in the acute phase of ischemic 
stroke, which can improve functional outcome significantly (1). However, not all patients 
experience a good functional outcome with intravenous thrombolytic therapy (IVT). Each 
ischemic stroke patient can be different from the other one considering some factors like 
baseline conditions and presence of stroke risk factors which may influence the outcome of 
IVT. Ability to predict good outcome shortly after admission can play an important role in 
decision making for the best treatment plan. It is also important for patients and their 
caregivers to have more realistic expectations of IVT, and maybe it can alter their decision 
to choose the treatment. There are discrepancies in the literature regarding prediction of 
patients’ outcomes who are going to receive rt-PA therapy. 
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For instance, it has been reported in some researches that 
HTN, DM, hyperlipidemia, AF, CHD are not prognostic 
factors for functional outcome (2-4), while in some other 
studies dyslipidemia, high BS (5), AF, CHD (6) are related 
to patients’ outcome. In addition, in some reports, ethnicity 
is found to be an important predictor of stroke outcome (7, 
8). The aim of the present study is to investigate the 
predictors of IVT good outcome in Iranian patients with 
ischemic stroke before rt-PA administration.  
 
 
Method 
Study participants: This is a retrospective study which was 
done at Firoozgar University Hospital, one of the major 
stroke referral centers in Tehran, Iran. A total of 118 patients 
treated with IVT (Alteplase) between June 2015 and 
November 2017 were enrolled in this study. Initially, there 
were 138 patients who had received IVT in our center during 
the mentioned time period, however 118 of them met the 
criteria to be evaluated in this study. Upon arrival in the 
hospital, medical and medication history was taken to 
evaluate the risk of bleeding in each patient. A quick 
neurological examination was performed by neurology team 
and stroke severity was assessed by using the National 
Institutes of Health Stroke Scale (NIHSS) score. Non-
contrast CT scan and following laboratory tests were 
requested immediately: Complete blood count test, Blood 
sugar, Creatinine and coagulation tests (INR, PT, PTT). 
Exclusion and inclusion criteria for IVT was defined based 
on AHA/ASA guideline. Eligible patients admitted within 
4.5 hours of symptom onset, received 0.9 mg/kg of rt-PA to 
the maximum dose of 90 mg intravenously (10% bolus, 90% 
infusion in 1 hour). All patients were admitted to stroke unit 
care after receiving IV-rt-PA for further management and 
rehabilitation. The exclusion criteria for this study were as 
following: 1- Patients who did not receive all calculated rt-
PA dose completely due to uncontrolled blood pressure after 
rt-PA administrationor any other reasons, 2- Those who 
received rt-PA beyond 4.5 hours of symptom onset, 3- 
Patients whose final diagnosis was not acute ischemic stroke 
despite receiving rt-PA (stroke mimics), 4- Patients who 
were not available for follow up or were not content for 
enrolling in this study. 
Data collecting: Hospital documents were retrospectively 
reviewed by a physician who was blind to patients' outcomes 
to collect the following data: demographic characteristics, 
initial systolic and diastolic blood pressure, symptom onset 
to needle time (OTN), door to needle time (DTN), stroke 
severity based on national institutes health stroke (NIHSS) 
score, past medical history of diabetes mellitus, 
hypertension, dyslipidemia, coronary artery disease, and past 
history of ischemic stroke. Those patients who had arterial 
fibrillation (AF) on cardiac monitoring at the time of 
admission or were known cases of AF were also determined 
as AF patients. The study was approved by the Iran 
University of Medical Sciences Ethics Committee. 
Outcome measurement: Three months after the admission 
of modified Rankin Scale (mRS) as the outcome 
measurement was evaluated by the telephone interview. 
Each interview lasted 10 to 20 minutes with patients or their 
primary caregivers to determine the score. Patients were 
classified into 2 groups: good outcome (mRS 0 to 2) and 
poor outcome (mRS 3 to 6).  
Statistical analysis: Continuous variables are expressed as 
meanSD, and categorical variables are expressed as counts 
(n) and percentage (%). Univariate analysis was done using 
t-test and chi-square test for continuous and categorical 
variables, respectively. Multivariable logistic regression was 
applied to determine the independent association between 
good outcome (mRS 0-2) or poor outcome (mRS 3-6) and 
clinical factors and laboratory results. The significance level 
was determined at p-value < 0.05. All analyses were done by 
SPSS Version 16. 
 
 
Results 
During the study period, between June 2015 and 
November 2017,133 patients received IVT in our hospital. 
Of those, 118 were included in this study. There were 78 
(66%) males and 40 (34%) females in this study, and the age 
range was 31-90 years with median 67.5. After a time period 
of 3 months, good outcome (mRS 0-2) was seen in 60 
(50.8%) patients and poor outcome in 58 (49.2%) patients. 
Table 1 compares the clinical characteristics and laboratory 
results of good outcome group with poor outcome group. 43 
(55%) males had good outcome and 35 (45%) had poor 
outcome. 17 (42%) females had good outcome and 23 (57%) 
had poor outcome. Age (P=0.002), NIHSS (P<0.001), AF 
(P=0.001) were significant in univariate analysis. After 
entering all variables in multivariable logistic regression, 
following factors were significantly related to mRS at 3 
months: NIHSS score (odds ratio [OR],0.61;95% confidence 
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interval [CI], 0.498-0.750; P<0.001), SBP (OR, 0.95; 95% CI, 
0.925-0.991; P=0.01), AF (OR, 0.09; 95% CI, 0.013- 0.708; 
P=0.02), CAD (OR,17.08; 95% CI, 0.013-0.708; P=0.003) 
(table 2). 
 
Table-1 Clinical features and laboratory findings in good outcome group vs poor outcome group 
Variable 
Total 
N = 118 
Good outcome 
N = 60 
Poor outcome 
N = 58 
p-value 
Age, mean (±SD) 66.12(13.46) 62.40(12.84) 69.96(13.11) 0.002 
SBP (mmHg) 154.35(26.55) 149.80(26.17) 159.06(26.34) 0.058 
DBP (mmHg)  93.66(21.10) 90.68(13.56) 96.75(26.54) 0.123 
DTN (min) 53.21(35.28) 49.58(33.05) 56.96(37.35) 0.258 
STN (min) 144.90(62.63) 143.26(63.79) 146.60(61.92) 0.774 
NIHSS 11.10(5.06) 7.96(4.23) 14.34(3.61) <0.001 
PLT 219.56(82.18) 216.01(70.22) 223.18(93.28) 0.639 
Initial plasma glucose (mg/dL) 169.95(78.15) 171.50(87.32) 168.36(68.11) 0.828 
Creatinine 1.15(0.43) 1.09(0.23) 1.22(0.57) 0.117 
Sex: male (%) 78(66.10) 43(55.12) 35(44.87) 0.194 
Previous stroke 25(21.20) 12(48) 13(52) 0.748 
Hypertension 82(69.50) 42(51.21) 40(48.78) 0.903 
Coronary artery disease 55(46.60) 30(54.54) 25(45.45) 0.453 
Diabetes mellitus 41(34.70) 22(53.65) 19(46.34) 0.656 
Dyslipidemia 28(23.70) 15(53.57) 13(46.42) 0.741 
Atrial fibrillation 24(20.30) 5(20.83) 19(62.67) 0.001 
Smoking 25(21.20) 14(56) 11(44) 0.562 
Note: SBP: Systolic blood pressure, DBS: Diastolic blood pressure, DTN: door to needle, STN: symptom to needle, NIHSS: 
National Institute Health Stroke Scale. 
 
Table-2 Logistic regression analysis predicting outcome of intravenous thrombolytic therapy for acute ischemic stroke patients 
 Adjusted estimation Crude estimation 
Variable OR (95% CI) P OR (95% CI) P 
Sex 0.415 (0.078 -  2.210) 0.303 .602 (.279 - 1.299) .196 
Previous stroke 0.904 (0.179 -   4.564) 0.902 .865 (.358 - 2.094) .748 
Hypertension 1.473 (0.282 -  7.693) 0.646 1.050 (.480 -2.299) .903 
Coronary artery disease 17.085 (2.544 -   114.722) 0.003 1.320 (.639 -2.726) .453 
Diabetes mellitus 0.578 (0.102 -   3.283) 0.536 1.188 (.556 -2.539) .656 
Dyslipidemia 0.403 (0.073  -  2.214) 0.296 1.154 (.493 -2.699) .741 
Smoking 0.345 (0.050 -  2.361) 0.278 1.300 (.535 -3.161) .562 
Atrial fibrillation 0.095 (0.013 -  0.708) 0.022 .187 (.064 - .542) .002 
Age 0.963 (0.916 -   1.011) 0.132 1.046 (1.015 -1.078) .003 
SBP 0.957 (0.925  -  0.991) 0.012 1.012 (.997 -1.027) .110 
DBP 1.000 (0.968 -   1.033) 0.999 1.014 (.995 -1.034) .142 
DTN 0.992 (0.970  -  1.013) 0.441 1.005 (.995 -1.016) .319 
OTN 1.000 (0.988 -   1.013) 0.962 1.001 (.995 -1.007) .762 
NIHSS 0.611 (0.498  -  0.750) < 0.001 1.431 (1.266 -1.618) .000 
PLT 0.993 (0.986-1.001) 0.082 1.001 (.997-1.006) .637 
Initial plasma glucose 1.002 (0.993-1.011) 0.624 .999 (.995-1.004) .827 
Creatinine 0.128 (0.010-1.692) 0.118 2.427 (.757-7.784) .136 
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Discussion 
The aim of this study was to evaluate the outcome 
predictors among Iranian patients shortly after admission. 
We found that 51% of our patients experienced good 
outcome (mRS2), and 49% experienced poor outcome 
(mRS 3-6). In current study, it was found that NIHSS score, 
systolic blood pressure, AF and CAD were significantly 
related to functional outcome among our patients who 
underwent IVT.  
We chose mRS 2 as the good outcome score because at 
this score patients are independent and can do their routine 
daily activities without any help. However, in some studies, 
other cutoffs were defined as good outcome (9). Previously 
the stroke-thrombolytic predictive instrument (TPI), 
multimodal outcome score for stroke thrombolysis (MOST) 
and DRAGON score have been introduced to predict 
outcome in patients who underwent IVT. Each of these 
scores has different criteria to predict the outcome (9-11).  
Our data suggest that higher NIHSS score and high systolic 
blood pressure at admission, history of AF and CAD were 
associated with poor outcome (mRS 3-6). Although 
intracranial hemorrhage (ICH) especially symptomatic ICH 
as a potential adverse effect of rt-PA can influence the 
outcome of IVT, we did not consider ICH in our study 
because the aim of this study was to determine predictive 
factors before the administration of rt-PA. 
Effect of NIHSS on outcome: NIHSS is an examination 
scale including 15 items for assessment of stroke severity. 
The total score is 0 to 42, the higher the score, the more 
severe is the stroke. Other studies came to the conclusion 
that NIHSS had good reliability and validity to determine the 
severity of neurologic deficit in stroke patients (12, 13).  
MOST and DRAGON scores, and also TPI score (only 
for poor outcome prediction), use NIHSS score to predict 
functional outcome. Our findings were consistent with other 
studies in which higher admission NIHSS score was 
associated with more unfavorable outcome, in both groups of 
patients who received IVT or not (14-18). In a recent study, 
NIHSS 15 was determined as a long term good prognostic 
factor in stroke patients who had received rt-PA at least 1 
year before assessment. We should also consider this fact 
that NIHSS may not be a good tool to assess the severity of 
stroke in posterior circulation strokes (19, 20).  It implies 
that if in our study the exact territory of stroke had been 
defined, probably the NIHSS score was less predictive for 
functional outcome. 
Effects of Systolic Blood Pressure on outcome: The 
correlation of baseline systolic blood pressure (SBP) with 
outcome of ischemic stroke has been discussed in several 
studies. Some studies suggested that higher SBP is 
associated with poor outcome outcome (21, 22) or good 
outcome (23).  
Some other studies found a U-shape relationship between 
SBP and outcome of ischemic stroke. High systolic blood 
pressure can cause more brain edema, stroke recurrence or 
intracranial pressure, while low blood pressure can extend 
the infarct area by lowering blood perfusion, increasing the 
risk of cardiovascular disease or cerebral reinfarction (24, 
25). 
In one study with 17398 participants from International 
Stroke Trial, there was a U-shape association between 
baseline SBP and death or dependency after 6 months. This 
study showed that those patients whose baseline SBP was 
between 140-179 had the better outcome than other patients, 
and the best outcome was in those whose SBP was around 
150 mmHg. In this study, almost 5% of patients had 
SBP<120 which was associated with the poor outcome due 
to cardiovascular events (25). 
 Of interest, in our study, there were also 6 (5.1%) 
patients with baseline SBP lower than 120 mmHg, among 
them 2 patients had poor outcome, which both of them had 
the history of ischemic heart disease and expired after about 
2 months due to myocardial infarction. In a more recent 
study in China in which only those stroke patients were 
assessed who underwent thrombolytic therapy within 4.5 
hours of their symptoms, it was noted that lower baseline 
SBP had a significant independent relationship with 
favorable outcome which was defined as mRS 0-1 (6).  
Effect of Atrial Fibrillation and Coronary Artery Disease 
on outcome: AF is a well-known cardiac risk factor for 
ischemic stroke. Ischemic stroke can be the initial 
presentation in AF patients or it can occur in anticoagulated 
AF cases. In our study population, 24 (20%) patients were 
defined as AF patients, either chronic or new cases of AF. It 
has been shown in some studies that AF patients have a 
greater risk of having poor outcome after stroke (25-27). 
Probably AF increases the risk of the second stroke (28). 
In addition, the malignant massive stroke which has the 
higher risk of mortality is more frequent in cardio-embolic 
origin of stroke (6). The worse outcome of ischemic stroke 
among AF patients has been also referred to the higher risk 
of hemorrhage in some studies (29). Cetiner et al. reported 
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that in their study, AF patients had even better functional 
outcome, maybe because this fact that cardiac originating 
embolisms are richer in fibrin compare to those which are 
originating from atherosclerotic plaques which are full of 
pellets, so embolic thromboses are more soluble while 
contacting with rt-PA (30).  
A recent study has suggested that poor outcome is higher 
in the elderly group of AF patients, and younger patients 
may experience better outcome (31).  
By coronary artery disease, we mean the history of the 
acute coronary syndrome and angina pectoralis. It has been 
shown in some studies that patients with the history of MI 
have more poor outcome after ischemic stroke (32). In our 
study, the presence of CAD was significantly different 
between good outcome patients and poor outcome ones. 
Stroke and coronary heart disease have common risk factors 
and pathophysiology.  
For example, AF as a predictor of poor outcome in stroke 
patients is also more prevalent in those who suffer from 
CAD. This is a limitation of real clinical scenario studies 
including ours. CAD and/or AF are independent predictors 
in some scores for overall ischemic stroke patients' outcome 
(32-34).  
But it is not included in any of the mentioned scores 
which assess outcome in patients who underwent IVT. 
Further studies will be needed to determine whether the 
presence of CAD or AF can be predictive of stroke outcome 
of patients who underwent IVT or not. Although in many 
studies advancing age has an important impact on 
thrombolytic therapy outcome (8-10). We did not find any 
association between age and outcome of IVT among our 
study patients. 
Study limitations: The limitation in this study is the 
retrospective nature of the study. We did not consider the 
radiologic features of each patient including the location and 
size of ischemia in the current study. We did not include 
previous medication and lipid profile in our study due to a 
considerable number of missing data. Further prospective 
studies with more patients are warranted to confirm our 
findings. 
In conclusions, according to our study in the emergency 
setting and before administration of rt-PA, higher NIHSS, 
higher initial systolic blood pressure and the presence of 
CAD history or AF are important factors which can predict 
functional outcome and dependency status 3 months after 
ischemic stroke. 
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